Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon PK in Hepatic Impairment
NCT05404529Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tavapadon in Parkinson's disease (PD) (3 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 7, Area Under the Plasma Concentration-time Curve from Time Zero to t at Day 7 and 1 more. Started Apr 2022; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05404529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404529.